Laura Mezquita

Scopus Author ID Loop profile Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 21

Top Topics

Small Cell Lung Cancer

Papillary Thyroid

Top Venues

British journal of cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

JCO precision oncology

Therapeutic advances in medical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Juan Carlos Laguna, Belén Pastor, Irene Nalda, Sara Hijazo-Pechero, Cristina Teixido, Miriam Potrony, Joan Antón Puig-Butillé, Laura Mezquita
Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications. British journal of cancer 130 (9) (2024)
Juan Carlos Laguna, Marco Tagliamento, Matteo Lambertini, James Hiznay, Laura Mezquita
Tackling Non-Small Cell Lung Cancer in Young Adults: From Risk Factors and Genetic Susceptibility to Lung Cancer Profile and Outcomes. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 44 (3) (2024)
Juan Carlos Laguna, Miguel Garcia-Pardo, Joao Alessi, Carlos Barrios, Navneet Singh, Humaid O Al-Shamsi, Herbert Loong, Miquel Ferriol, Gonzalo Recondo, Laura Mezquita
Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology. Therapeutic advances in medical oncology 16 (2024)
Juan Carlos Laguna, Belén Pastor, Irene Nalda, Sara Hijazo-Pechero, Cristina Teixido, Miriam Potrony, Joan Antón Puig-Butillé, Laura Mezquita
Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications. British journal of cancer (2024)
Juan Carlos Laguna, Belén Pastor, Irene Nalda, Sara Hijazo-Pechero, Cristina Teixido, Miriam Potrony, Joan Antón Puig-Butillé, Laura Mezquita
Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications. British journal of cancer 130 (9) (2024)
Juan Carlos Laguna, Belén Pastor, Irene Nalda, Sara Hijazo-Pechero, Cristina Teixido, Miriam Potrony, Joan Antón Puig-Butillé, Laura Mezquita
Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications. British journal of cancer 130 (9) (2024)
Juan Carlos Laguna, Belén Pastor, Irene Nalda, Sara Hijazo-Pechero, Cristina Teixido, Miriam Potrony, Joan Antón Puig-Butillé, Laura Mezquita
Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications. British journal of cancer 130 (9) (2024)
Juan Carlos Laguna, Miguel Garcia-Pardo, Joao Alessi, Carlos Barrios, Navneet Singh, Humaid O Al-Shamsi, Herbert Loong, Miquel Ferriol, Gonzalo Recondo, Laura Mezquita
Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology. Therapeutic advances in medical oncology 16 (2024)
Juan Bautista Blaquier, Sandra Ortiz-Cuaran, Biagio Ricciuti, Laura Mezquita, Andrés Felipe Cardona, Gonzalo Recondo
Tackling osimertinib resistance in EGFR mutant non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Yoann Pradat, Julien Viot, Andrey A Yurchenko, Konstantin Gunbin, Luigi Cerbone, Marc Deloger, Guillaume Grisay, Loic Verlingue, Veronique Chung-Scott, Ismael Padioleau, Leonardo Panunzi, Stefan Michiels, Antoine Hollebecque, Gerome Jules-Clement, Laura Mezquita, Antoine Laine, Yohann Loriot, Benjamin Besse, Luc Friboulet, Fabrice Andre, Paul-Henry Cournede, Daniel Gautheret, Sergey I Nikolaev
Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer. Cancer discovery (2023)
Edurne Arriola, Reyes Bernabé, Rosario García Campelo, Michele Biscuola, Ana Belén Enguita, Fernando López-Ríos, Rafael Martínez, Laura Mezquita, Sarai Palanca Suela, María Jesús Pareja, Jon Zugazagoitia, Natalia Arrabal, J Francisco García, David Carcedo, Enrique de Álava
Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers. JCO precision oncology 7 (2023)
Juan Bautista Blaquier, Sandra Ortiz-Cuaran, Biagio Ricciuti, Laura Mezquita, Andrés Felipe Cardona, Gonzalo Recondo
Tackling osimertinib resistance in EGFR mutant non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Juan Bautista Blaquier, Sandra Ortiz-Cuaran, Biagio Ricciuti, Laura Mezquita, Andrés Felipe Cardona, Gonzalo Recondo
Tackling osimertinib resistance in EGFR mutant non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Edurne Arriola, Reyes Bernabé, Rosario García Campelo, Michele Biscuola, Ana Belén Enguita, Fernando López-Ríos, Rafael Martínez, Laura Mezquita, Sarai Palanca Suela, María Jesús Pareja, Jon Zugazagoitia, Natalia Arrabal, J Francisco García, David Carcedo, Enrique de Álava
Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers. JCO precision oncology 7 (2023)
Boris Duchemann, Marie Naigeon, Edouard Auclin, Roberto Ferrara, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, François-Xavier Danlos, Laura Mezquita, Caroline Caramella, Aurélien Marabelle, Benjamin Besse, Nathalie Chaput
CD8 + PD-1 + to CD4 + PD-1 + ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers. Journal for immunotherapy of cancer 10 (2) (2022)
Rafael López-Castro, Tania García-Peña, Xabier Mielgo-Rubio, Mariona Riudavets, Cristina Teixidó, Noelia Vilariño, Felipe Couñago, Laura Mezquita
Targeting molecular alterations in non-small-cell lung cancer: what's next? Personalized medicine 19 (4) (2022)
Alessio Cortellini, Biagio Ricciuti, Victor R Vaz, Davide Soldato, Joao M Victor Alessi, Filippo G Dall'Olio, Giuseppe L Banna, Sethupathi Muthuramalingam, Samuel Chan, Margarita Majem Tarruella, Aida Piedra, Giuseppe Lamberti, Elisa Andrini, Alfredo Addeo, Alex Friedlaender, Francesco Facchinetti, Teresa Gorría, Laura Mezquita, Delphine Hoton, Lacroix Valerie, Frank Aboubakar Nana, James Artingstall, Charles Comins, Massimo Di Maio, Andrea Caglio, Judith Cave, Hayley McKenzie, Thomas Newsom-Davis, Joanne S Evans, Marcello Tiseo, Antonio D'Alessio, Claudia A M Fulgenzi, Benjamin Besse, Mark M Awad, David James Pinato
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. Journal for immunotherapy of cancer 10 (2) (2022)
Balázs G Madas, Jan Boei, Nora Fenske, Werner Hofmann, Laura Mezquita
Effects of spatial variation in dose delivery: what can we learn from radon-related lung cancer studies? Radiation and environmental biophysics 61 (4) (2022)
Gonzalo Recondo, Laura Mezquita
Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. Future oncology (London, England) 16 (23) (2021)
Laura Mezquita, David Planchard
Durvalumab for the treatment of non-small cell lung cancer. Expert review of respiratory medicine 12 (8) (2018)
Laura Mezquita, Andreea Varga, David Planchard
Safety of osimertinib in EGFR-mutated non-small cell lung cancer. Expert opinion on drug safety 17 (12) (2018)